Comparison of N-[11C]methyl-norchloroepibatidine and N-[11C]methyl- 2-(2-pyridyl)-7-azabicyclo[2.2.1]heptane with N-[11C]methyl-epibatidine in small animal PET studies

Nuclear Medicine and Biology

Volumn 27, Issue 3, 2000, Pages 239-247

  Spang, J E ^a   Patt, J T ^a   Westera, G ^a   Schubiger, P A ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Epibatidine; Nicotinic receptor; Positron emission tomography

Indexed keywords

CARBON 11; EPIBATIDINE; N METHYL 2 (2 PYRIDYL) 7 AZABICYCLO[2.2.1]HEPTANE; N METHYL EPIBATIDINE; N METHYL NORCHLOROEPIBATIDINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG; CYTOSINE; DIAGNOSTIC AGENT; FUSED HETEROCYCLIC RINGS; LIPID; N METHYL 2PABH; N METHYL NORCHLOROEPB; N-METHYL-2PABH; N-METHYL-NORCHLOROEPB; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; CHIRALITY; CHOLINERGIC SYSTEM; ENANTIOMER; ISOTOPE LABELING; NEURORADIOLOGY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; PHYSICAL CHEMISTRY; SPRAGUE DAWLEY RAT; STEREOISOMERISM; ULTRAVIOLET SPECTROPHOTOMETRY; WHOLE BODY COUNTING;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSINE; INJECTIONS, INTRAVENOUS; LIPIDS; MALE; PYRIDINES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 0033625544     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(00)00080-9     Document Type: Article

References (52)

1. Abraham H.M., Chadha H.S. Applications of a solvation equation to drug transport properties. Pliska B.T.V., van de Waterbeemd H. Lipophilicity in Drug Action and Toxicology. 1996;311-338 VCH, New York.
2. Abraham M.H., Chadha H.S., Mitchell R.C. Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J. Pharm. Sci. 83:1994;1257-1268.
3. Aoyagi S., Tanaka R., Naruse M., Kibayashi C. Asymmetric total synthesis of (-)-epibatidine. Tetrahedron Lett. 39:1998;4513-4516.
4. Aubert I., Araujo D.M., Cecyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58:1992;529-541.
5. Avenoza A., Busto J.H., Cativiela C., Peregrina J.M. A versatile and stereoselective synthesis of (+/-)-epibatidine. Synthesis-Stuttgart. 9:1998;1335-1338.
6. Badio B., Shi D., Garraffo H.M., Daly J.W. Antinociceptive effects of the alkaloid epibatidine Further studies on involvement of nicotinic receptors . Drug Dev. Res. 36:1995;46-59.
7. Bertrand S., Patt J.T., Spang J.E., Westera G., Schubiger P.A., Bertrand D. Neuronal nAChRs stereoselective to non-natural epibatidine derivatives. FEBS Lett. 450:1999;273-279.
8. Brioni J.D., Decker M.W., Sullivan J.P., Arneric S.P. The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv. Pharmacol. 37:1997;153-214.
9. Broka C.A. Synthetic approaches to epibatidine. Med. Chem. Res. 4:1994;449-460.
10. Clayton S.C., Regan A.C. A total synthesis of (±)-epibatidine. Tetrahedron Lett. 34:1993;7493-7496.
11. Dale J.A., Dull D.L., Mosher H.S. alpha-Methoxy-alpha-trifluormethylphenylacetic acid, a versatile reagent for determination of enantiomeric composition of alcohols and amines. J. Org. Chem. 34:1969;2543-2549.
12. Dehmlow E.V. Epibatidine competition Synthetic work on a novel natural analgetic . J. Prak. Chem.-Chem. Ztg. 337:1995;167-174.
13. Ding Y.-S., Molina P.E., Fowler J.S., Logan J., Volkow N.D., Kuhar M.J., Caroll F.I. Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP Kinetics, nicotinic effect and toxicity . Nucl. Med. Biol. 26:1999;139-148.
14. Dischino D.D., Welch M.J., Kilbourn M.R., Raichel M.E. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med. 24:1983;1030-1083.
15. Gatley S.J., Ding Y.S., Brady D., Gifford A.N., Dewey S.L., Carroll F.I., Fowler J.S., Volkow N.D. In vitro and ex vivo autoradiographic studies of nicotinic acetylcholine receptors using [F-18]fluoronorchloroepibatidine in rodent and human brain. Nucl. Med. Biol. 25:1998;449-454.
16. Grünwald F., Biersack H.-J. Nicotine receptor mapping. Eur. J. Nucl. Med. 23:1996;1012-1016.
17. Halldin C., Nagren K., Swahn C.G., Langstrom B., Nyback H. (S)- and (R)-[11C]nicotine and the metabolite (R/S)-[11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET. Int. J. Rad. Appl. Instrum. B. 19:1992;871-880.
18. Hansch C., Clayton J.M. Lipophilic character and biological activity of drugs II The parabolic case . J. Pharm. Sci. 62:1973;1-21.
19. Horti A., Scheffel U., Stathis M., Finley P., Ravert H.T., London E.D., Dannals R.F. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J. Nucl. Med. 38:1997;1260-1265.
20. Horti A.G., Scheffel U., Kimes A.S., Musachio J.L., Ravert H.T., Mathews W.B., Zhan Y.G., Finley P.A., London E.D., Dannals R.F. Synthesis and evaluation of N-[C-11]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. J. Med. Chem. 41:1998;4199-4206.
21. Huang D.F., Shen T.Y. A versatile total synthesis of epibatidine and analogs. Tetrahedron Lett. 34:1993;4477-4480.
22. Larsen P., Ulin J., Dahlstrøm K., Jensen M. Synthesis of [11C]iodomethane by iodination of [11C]methane. Appl. Radiat. Isotopes. 48:1997;153-157.
23. Larsen P., Ulin J., Dahlstrøm K.-J. A new method for production of [11C]-labelled methyl iodide from [11C]methane. J. Labelled Compd. Radiopharm. 27:1995;73-75.
24. Leo A., Hansch C., Elkins D. Partition coefficients and their uses. Chem. Rev. 71:1971;525-616.
25. Lundqvist H., Nordberg A., Hartvig P., Langstrom B. (S)-(-)-[11C]Nicotine binding assessed by PET A dual tracer model evaluated in the rhesus monkey brain . Alz. Dis. Assoc. Dis. 12:1998;238-246.
26. Molina P.E., Ding Y.S., Carroll F.I., Liang F., Volkow N.D., Pappas N., Kuhar M., Abumrad N., Gatley S.J., Fowler J.S. Fluoro-norchloroepibatidine Preclinical assessment of acute toxicity . Nucl. Med. Biol. 24:1997;743-747.
27. Musachio J. L., Scheffel U., Villemagne V., Horti A., Finley P., Xiao Y., Davila-Garcia M., Kellar K. J., Ravert H. T., Mathews W. B., London E. D. and Dannals R. F. (1997) [C-11] and [I-123/125] (+)- and (-)-MeIPH: Analogs of epibatidine for in vivo studies of nicotinic acetylcholine receptors. J. Nucl. Med. 38, 65 P.
28. Musachio J.L., Villemagne V.L., Scheffel U., Stathis M., Finley P., Horti A., London E.D., Dannals R.F. [125/123I]IPH A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors . Synapse. 26:1997;392-399.
29. Muzic R.F. Jr, Berridge M.S., Friedland R.P., Zhu N., Nelson D. PET quantification of specific binding of carbon-11-nicotine in human brain. J. Nucl. Med. 39:1998;2048-2054.
30. Nordberg A., Hartvig P., Lilija A., Viatanen M., Amberla K., Lundquist H., Andersson Y., Ulin J., Winbald B., Långström B. Decreased uptake and binding of [11C]nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J. Neural. Transm. 2:1990;215-224.
31. Nordberg A., Hartvig P., Lilja A., Viitanen M., Amberla K., Lundqvist H., Andersson J., Nyback H., Ulin J., Anderson Y., Winblad B., Långström B. Nicotine receptors in the brain of patients with Alzheimer's disease. Studies with [11C]nicotine and positron emission tomography. Acta. Radiol. Suppl. 376:1991;165-166.
32. Nordberg A., Winbald B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:1986;115-119.
33. Nyback H., Halldin C., Ahlin A., Curvall M., Eriksson L. PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain Difficulties in visualizing specific receptor binding in vivo . Psychopharmacology. 115:1994;31-36.
34. Nyback H., Nordberg A., Langstrom B., Halldin C., Hartvig P., Ahlin A., Swahn C.G., Sedvall G. Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography. Prog. Brain. Res. 79:1989;313-319.
35. Patt J.T., Spang J.E., Westera G., Buck A., Schubiger P.A. Synthesis and in vivo studies of [C11]N-methylepibatidine Comparison of the stereoisomers . Nucl. Med. Biol. 26:1999;165-173.
36. Patt J. T., Spang J. E., Westera G., Buck A. and Schubiger P. A. (submitted) Synthesis and in vivo study of the stereoisomers of [11C]N-methylhomoepibatidine. Neuropharmacology.
37. Patt J.T., Spang J.E., Westera G., Schubiger P.A. [11C]N-Methyl-epibatidine and [11C]N-methyl-homoepibatidine Comparison of the stereoisomers in vivo . Eur. J. Nucl. Med. 25:1998;854. (Abstract).
38. Patt J.T., Westera G., Buck A., Fletcher S.R., Schubiger P.A. [11C]N-Methyl- and [18F]fluoroethylepibatidine Ligands for the neuronal nicotinic receptor . J. Labelled Compd. Radiopharm. 37:1995;355-356.
39. Patt J.T., Westera G., Buck A., Schubiger P.A. Synthesis of [11C]-N-methylhomoepibatidine and biodistribution in mice. J. Labelled Compd. Radiopharm. 40:1997;528-530.
40. Ploux L., Mastrippolitio R. In vivo radiolabel quantification in small-animal models. Nucl. Med. Biol. 25:1999;737-742.
41. Scherrer R.A., Howard S.M. Use of distribution coefficients in quantitative structure-activity relationships. J. Med. Chem. 20:1977;53-58.
42. Seiler P. Interconversion of lipohilicities from hydrocarbon/water systems into the octanol/water system. Eur. J. Med. Chem. 9:1974;473-479.
43. Sirisoma N.S., Johnson C.R. alpha-iodocycloalkenones Synthesis of (+/-)-epibatidine . Tetrahedron Lett. 39:1998;2059-2062.
44. Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannell L., Daly J.W. Epibatidine A novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadorian poison frog . J. Am. Chem. Soc. 114:1992;3475-3478.
45. Spang J. E., Bertrand S., Patt J. T., Westera G. and Bertrand D. (accepted) Chemical modifications of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acethylcholine receptors. Chemistry and Biology.
46. Spang J.E., Patt J.T., Westera G., Schubiger P.A. Synthesis and [11C]-radiolabelling of dechloroepibatidine and 2PABH, two potential radioligands for studying the central nAChRs in vivo. J. Labelled Compd. Radiopharm. 42:1999;761-771.
47. Spang J.E., Patt J.T.W., Bertrand S., Bertrand D., Westera G., Schubiger P.A. Synthesis and electrophysiological studies of a novel epibatidine analogue. J. Recept. Signal Tr. R. 19:1999;521-531.
48. Tayar N., el Tsai R.-S, Testa B., Carrupt P.-A., Leo A. Partitioning of solutes in different solvent systems The contribution of hydrogen-bonding capacity and polarity . J. Pharm. Sci. 80:1991;590-598.
49. Villemagne V.L., Horti A., Scheffel U., Ravert H.T., Finley P., Clough D.J., London E.D., Wagner H.N. Jr, Dannals R.F. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. J. Nucl. Med. 38:1997;1737-1741.
50. van de Waterbeemd H., Testa B. The parametrization of lipophilicity and other stuctural properties in drug design. Adv. Drug Res. 16:1987;87-225.
51. Watt A.P., Verrier H.M., O'Connor D. Resolution of synthetic (+)- and (-)-epibatidine by chiral high performance liquid chromatography and identification of the natural enantiomer. J. Liq. Chromatogr. R. T. 17:1994;1257-1264.
52. Young R.C., Mitchell R.C., Brown T.H., Ganellin C.R., Griffiths R., Jones M., Rana K.K., Saunders D., Smith I.R., Sore N.E., Wilks T.J. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J. Med. Chem. 31:1988;656-671.